12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Optina danazol: Phase IIb started

Ampio began a placebo-controlled, U.S. Phase IIb trial to evaluate 0.5 and 1 mg/BMI oral Optina daily for 12 weeks in 450 adult patients with recent onset DME. A 4-week washout period following the treatment period will be used to determine...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >